Management of the Axilla after Neoadjuvant Systemic Therapy.

ABSTRACT:

Opinion statement

As the use of neoadjuvant systemic therapy (NAST) increases, the optimal management of the axilla has become increasingly complex. Consensus among professional organizations is that those patients with clinically negative axillary nodes who are being considered for NAST should undergo a sentinel lymph node (SLN) biopsy following NAST. If a positive SLN is subsequently identified, an axillary lymph node dissection (ALND) is the current standard of care. For patients with clinically node-positive disease, SLN biopsy is a reasonable option for those with a good response to NAST. Patients should undergo SLN mapping with a dual dye technique. Additionally, at least 2 lymph nodes should be removed, including the previously biopsied and marked lymph node with cancer. In

SUBMITTER: Stankowski-Drengler TJ 

PROVIDER: S-EPMC7474973 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature